Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Brigham and Women's Hospital
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of SARS-CoV-2 infection by RT-PCR or another approved laboratory test ≤ 3 days before enrollment or ≤ 14 days before enrollment with progressive disease suggestive of ongoing SARS-CoV-2 infection; retesting allowed
Current hospitalization for ≤ 14 days with SARS-CoV-2 infection at the time of enrollment
Use of supplemental oxygen or oxygen saturation ≤ 94% on room air
Age ≥ 40
May receive antiviral medication (e.g., remdesivir, lopinavir/ritonavir, oseltamivir, favipiravir), antibiotics (e.g., azithromycin), chloroquine, hydroxychloroquine, corticosteroids, statins, anticoagulation, antiplatelet agents (e.g., aspirin) and/or convalescent plasma from recovered individuals off study and/or on study if permitted by the other protocol
You may not be if
Prior or planned treatment with interleukin inhibitors (e.g., tocilizumab, canakinumab, sarilumab) or TNF-α inhibitors within 14 days of enrollment
Prior lobectomy or pneumonectomy
Prior thoracic radiotherapy with cumulative lung V20 \> 15% to either lung within 1 year of enrollment, or any radiotherapy resulting in a maximum lung dose of 100 cGy or higher within 14 days of enrollment
Prior chemotherapy or other systemic therapy with potential for pulmonary toxicity or radiosensitization within 14 days or 5 half-lives, whichever is greater, of enrollment, e.g., bleomycin or gemcitabine
Prior cancer immunotherapy with an immune checkpoint inhibitor within 60 days of enrollment
Severe pre-existing heart disease, e.g., New York Heart Association (NYHA) functional class ≥ 3 congestive heart failure
History of bone marrow or solid organ transplantation
Known history of autoimmune collagen vascular disease, e.g., scleroderma
Known hereditary syndrome with increased sensitivity to ionizing radiation, e.g., ataxia-telangiectasia or Fanconi anemia
Pregnancy
Inability to be positioned supine and flat for radiation planning and delivery
Inability to provide informed consent or lack of an authorized representative who can provide informed consent
